-
Synthetic Biology, Genomics & Advanced Therapeutics1 day agoSTAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
Recent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.
-
Synthetic Biology, Genomics & Advanced Therapeutics1 day agoBonjour Genomics: A Video from ASHG
GEN editors Uduak Thomas and Julianna LeMieux, PhD, recap ASHG, highlighting key sessions, Ultima Genomics’ user group meeting, Illumina news, and insights from PacBio’s new CEO...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 days agoArtiva to quit autoimmune cell therapy work, cut staff after patient deaths
The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.
-
Synthetic Biology, Genomics & Advanced Therapeutics2 days agoAfter 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce
Artiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 days agoSTAT+: Nonprofit resurrects shelved gene therapy after startup shuts down
Last year, U.K. gene therapy startup Bloomsbury Genetic Therapies announced it was shutting down after dosing just one patient. Now, a nonprofit is resurrecting its lead program:
-
Synthetic Biology, Genomics & Advanced Therapeutics2 days agoASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers
Blood cancers carry complex genomic rearrangements that no single assay fully captures. At ASHG 2026 in Montréal, Nabsys presented early data comparing its Electronic Genome Mapping...
-
Synthetic Biology, Genomics & Advanced Therapeutics3 days agoAnother autoimmune CAR-T death; Treasury zeroes in on China deals
A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
